EU Regulator Approves AI-Powered Tool for Fatty Liver Disease Trials
2025-03-20Reuters
The European Medicines Agency has given the green light to the use of an innovative AI tool, AIM-NASH, in clinical trials for non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. This AI-powered technology aims to enhance the accuracy ...Read more
